Leerink Partners maintains market perform rating on Nurix stock

Leerink Partners reaffirmed its Market Perform rating for Nurix Therapeutics (NRIX) with a $16 price target after Sanofi (SNY) exercised its option to license Nurix’s STAT6 program, triggering a $15 million payment. While Nurix's stock rose on the news and positive data from Kymera Therapeutics' STAT6 program, analysts suggest the company's future performance hinges on the progress of its BTK degrader, bexobrutideg, for which Phase 1 data and pivotal study guidance are expected this month. Separately, TD Cowen maintains a Hold rating on Sanofi with a $67 price target, citing confidence in Dupixent's financial guidance and anticipating strong growth for Beyfortus, its RSV monoclonal antibody.

Analysis

Leerink Partners reaffirmed its Market Perform rating and a $16.00 price target for Nurix Therapeutics (NASDAQ: NRIX) after its partner Sanofi (NASDAQ:SNY), a pharmaceutical company with a $119.29 billion market capitalization and 71% gross profit margin, exercised its option to license Nurix’s STAT6 program, resulting in a $15 million payment to Nurix. This decision, along with positive Phase 1 data from Kymera Therapeutics’ (NASDAQ: KYMR) KT-621, has increased interest in STAT6-targeted therapies and led to a rise in NRIX stock. Despite this positive development for the STAT6 program, analysts indicate that Nurix's future stock performance will be more significantly influenced by the progress of its BTK degrader, bexobrutideg, in chronic lymphocytic leukemia. Updated Phase 1 data for bexobrutideg and guidance on pivotal studies are expected later this month, though the program faces a competitive landscape and complex development. Separately, Sanofi, which reported $48.87 billion in revenue over the last twelve months and maintains a 'Good' financial health score according to InvestingPro, has a Hold rating and a $67 price target from TD Cowen. Sanofi's management expressed confidence in meeting financial guidance for its leading product, Dupixent, and highlighted positive developments such as its Covid vaccine Biologics License Application approval and strong growth expectations for Beyfortus, its RSV monoclonal antibody, with projected peak sales between €2 billion and just under €3 billion and an anticipated 80% market share for RSV monoclonal antibodies at their peak.

Key Decisions for Investors

• Investors in Nurix Therapeutics should view the $15 million Sanofi milestone for the STAT6 program as a positive, de-risking event, but focus intently on the upcoming Phase 1 data and pivotal study plans for bexobrutideg, as this asset remains the primary determinant of future valuation despite a challenging competitive environment.
• For Sanofi, the licensing of Nurix's STAT6 program is a modest expansion of its pipeline; its investment appeal continues to be underpinned by strong financials, the sustained outlook for Dupixent, and significant growth potential from Beyfortus, which is expected to achieve substantial market penetration and sales.
• The positive developments in STAT6-targeted therapies, including Kymera's data and Sanofi's licensing of Nurix's program, may warrant increased attention to this therapeutic area, though direct investment in Nurix carries significant event risk tied to the success of its bexobrutideg program.